{
    "Clinical Trial ID": "NCT00975676",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Triptorelin Plus Tamoxifen",
        "  Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.",
        "INTERVENTION 2: ",
        "  Triptorelin Plus Exemestane",
        "  Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed resected breast cancer",
        "  Concurrent enrollment on clinical trial IBCSG-2402 (SOFT trial) required",
        "  Randomized to receive triptorelin in combination with either tamoxifen citrate or exemestane",
        "  Hormone receptor status:",
        "  Estrogen receptor- and/or progesterone receptor-positive tumor",
        "  PATIENT CHARACTERISTICS:",
        "  Premenopausal",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Estrogen Levels (Estradiol [E2], Estrone [E1], and Estrone Sulphate [E1S]) at Different Time Points During the First 4 Years of Treatment With Triptorelin (Trip) in Combination With Either Tamoxifen (T) or Exemestane (E), IBCSG 24-02 SOFT-EST Substudy",
        "  Estrogen levels (estradiol [E2], estrone [E1], and estrone sulphate [E1S]) were measured at the following time points for the SOFT-EST: 0 (baseline), 3, 6, 12, 18, 24, 36, and 48 months after randomization. Some of these samples were not used, including un-scheduled sample, post surgery or vaginal bleeding, samples taken post early discontinuation (ED) or discontinuation of GnRH injections.",
        "  Time frame: 0 (baseline), 3, 6, 12, 18, 24, 36, and 48 months after randomization",
        "Results 1: ",
        "  Arm/Group Title: Triptorelin Plus Tamoxifen",
        "  Arm/Group Description: Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.",
        "  Overall Number of Participants Analyzed: 26",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: pg/mL  Estradiol (E2) levels at baseline (0 months): 26 participants",
        "  109.81         (119.151)",
        "  Estradiol (E2) levels at 3 months: 25 participants",
        "  4.876         (7.123)",
        "  Estradiol (E2) levels at 6 months: 24 participants",
        "  3.761         (2.02)",
        "  Estradiol (E2) levels at 12 months: 20 participants",
        "  4.013         (2.765)",
        "  Estradiol (E2) levels at 18 months: 20 participants",
        "  7.306         (16.325)",
        "  Estradiol (E2) levels at 24 months: 15 participants",
        "  4.453         (3.347)",
        "  Estradiol (E2) levels at 36 months: 14 participants",
        "  3.704         (2.138)",
        "  Estradiol (E2) levels at 48 months: 14 participants",
        "  5.914         (8.959)",
        "  Estrone (E1) levels at baseline (0 months): 26 participants",
        "  60.27         (52.4)",
        "  Estrone (E1) levels at 3 months: 25 participants",
        "  17.8         (6.73)",
        "  Estrone (E1) levels at 6 months: 24 participants",
        "  18.66         (7.54)",
        "  Estrone (E1) levels at 12 months: 21 participants",
        "  19.05         (8.4)",
        "  Estrone (E1) levels at 18 months: 20 participants",
        "  18.64         (9.35)",
        "  Estrone (E1) levels at 24 months: 15 participants",
        "  18.96         (7.63)",
        "  Estrone (E1) levels at 36 months: 14 participants",
        "  19.49         (7.32)",
        "  Estrone (E1) levels at 48 months: 14 participants",
        "  19.14         (7.24)",
        "  Estrone sulfate (E1S) levels at baseline (0 months): 26 participants",
        "  1437         (1825.06)",
        "  Estrone sulfate (E1S) levels at 3 months: 25 participants",
        "  281.4         (183.44)",
        "  Estrone sulfate (E1S) levels at 6 months: 24 participants",
        "  259         (167.23)",
        "  Estrone sulfate (E1S) levels at 12 months: 21 participants",
        "  278.5         (236.38)",
        "  Estrone sulfate (E1S) levels at 18 months: 20 participants",
        "  281.8         (160.6)",
        "  Estrone sulfate (E1S) levels at 24 months: 14 participants",
        "  242.6         (96.75)",
        "  Estrone sulfate (E1S) levels at 36 months: 14 participants",
        "  249.4         (113.27)",
        "  Estrone sulfate (E1S) levels at 48 months: 13 participants",
        "  231.1         (93.46)",
        "Results 2: ",
        "  Arm/Group Title: Triptorelin Plus Exemestane",
        "  Arm/Group Description: Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.",
        "  Overall Number of Participants Analyzed: 83",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: pg/mL  Estradiol (E2) levels at baseline (0 months): 81 participants",
        "  96.55         (151.235)",
        "  Estradiol (E2) levels at 3 months: 67 participants",
        "  3.973         (8.439)",
        "  Estradiol (E2) levels at 6 months: 66 participants",
        "  3.672         (8.006)",
        "  Estradiol (E2) levels at 12 months: 68 participants",
        "  2.486         (5)",
        "  Estradiol (E2) levels at 18 months: 65 participants",
        "  2.527         (6.204)",
        "  Estradiol (E2) levels at 24 months: 62 participants",
        "  2.52         (6.566)",
        "  Estradiol (E2) levels at 36 months: 60 participants",
        "  1.654         (2.764)",
        "  Estradiol (E2) levels at 48 months: 50 participants",
        "  9.073         (57.307)",
        "  Estrone (E1) levels at baseline (0 months): 81 participants",
        "  65.42         (78.12)",
        "  Estrone (E1) levels at 3 months: 67 participants",
        "  2.93         (3.33)",
        "  Estrone (E1) levels at 6 months: 66 participants",
        "  2.73         (3.12)",
        "  Estrone (E1) levels at 12 months: 68 participants",
        "  3.71         (6.35)",
        "  Estrone (E1) levels at 18 months: 65 participants",
        "  8.47         (33.42)",
        "  Estrone (E1) levels at 24 months: 62 participants",
        "  4.69         (9.16)",
        "  Estrone (E1) levels at 36 months: 60 participants",
        "  4.93         (9.16)",
        "  Estrone (E1) levels at 48 months: 50 participants",
        "  8.53         (35.07)",
        "  Estrone sulfate (E1S) levels at baseline (0 months): 81 participants",
        "  1371         (1763.84)",
        "  Estrone sulfate (E1S) levels at 3 months: 67 participants",
        "  56.02         (133.71)",
        "  Estrone sulfate (E1S) levels at 6 months: 66 participants",
        "  54.7         (97.66)",
        "  Estrone sulfate (E1S) levels at 12 months: 68 participants",
        "  47.31         (130.45)",
        "  Estrone sulfate (E1S) levels at 18 months: 64 participants",
        "  63.52         (175.19)",
        "  Estrone sulfate (E1S) levels at 24 months: 59 participants",
        "  73.56         (258.29)",
        "  Estrone sulfate (E1S) levels at 36 months: 60 participants",
        "  53.27         (151.03)",
        "  Estrone sulfate (E1S) levels at 48 months: 46 participants",
        "  112         (556.81)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/0",
        "Adverse Events 2:",
        "  Total: 0/0"
    ]
}